CONTACT US
Home > Inhibitors/Agonists> > Razoxane, (R)-
24613-06-7-Razoxane, (R)- Razoxane, (R)-

Razoxane, (R)-

For research use only. Not for therapeutic Use.

  • CAT Number: I035454
  • CAS Number: 24613-06-7
  • Molecular Formula: C11H16N4O4
  • Molecular Weight: 268.27
  • Purity: 98%
Inquiry Now
Related Small Molecules: 5-A-RU-PABC-Val-Cit-Fmoc     DZD1516     GCN2-IN-7    

Razoxane, (R)- exhibits antiangiogenic effects.


Catalog Number I035454
CAS Number 24613-06-7
Synonyms

Razoxane, (R)-; ICRF-186; ICRF 186; ICRF186; NSC-169779; NSC 169779; NSC169779; Levrazoxane;

Molecular Formula C11H16N4O4
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name (R)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)
InChI InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m1/s1
InChIKey BMKDZUISNHGIBY-SSDOTTSWSA-N
SMILES C[C@@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
Reference

1: Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, Woronoff-Lemsi MC, Deconinck E. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014 Apr;39(2):168-74. doi: 10.1111/jcpt.12124. Epub 2014 Jan 3. PubMed PMID: 24384030.
2: Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH. Late Mortality After Dexrazoxane Treatment: A Report From the Children’s Oncology Group. J Clin Oncol. 2015 Aug 20;33(24):2639-45. doi: 10.1200/JCO.2014.59.4473. Epub 2015 May 26. PubMed PMID: 26014292; PubMed Central PMCID: PMC4534526.
3: Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, Harris AL. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer. 2003 Jul 21;89(2):262-7. PubMed PMID: 12865914; PubMed Central PMCID: PMC2394254.
4: Klenner T, Wingen F, Keppler B, Valenzuela-Paz P, Amelung F, Schmähl D. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis. 1990 Jul-Aug;8(4):345-59. PubMed PMID: 2350920.
5: Sun F, Qi X, Geng C, Li X. Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci. 2015 May;349(5):406-12. doi: 10.1097/MAJ.0000000000000432. PubMed PMID: 25723884.
6: Neckář J, Boudíková A, Mandíková P, Stěrba M, Popelová O, Mikšík I, Dabrowská L, Mráz J, Geršl V, Kolář F. Protective effects of dexrazoxane against acute ischaemia/reperfusion injury of rat hearts. Can J Physiol Pharmacol. 2012 Sep;90(9):1303-10. doi: 10.1139/y2012-096. Epub 2012 Aug 22. PubMed PMID: 22913659.
7: Kamat P, Vandenberghe S, Christen S, Bongoni AK, Meier B, Rieben R, Khattab AA. Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs. PLoS One. 2016 Dec 21;11(12):e0168541. doi: 10.1371/journal.pone.0168541. eCollection 2016. PubMed PMID: 28002439; PubMed Central PMCID: PMC5176296.
8: Hasinoff BB. Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos. 1993 Sep-Oct;21(5):883-8. PubMed PMID: 7902252.
9: Baldwin JR, Lewis RC, Phillips BA, Overmyer SK, Hatfield NZ, Narang PK. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Biopharm Drug Dispos. 1996 Aug;17(6):541-50. PubMed PMID: 8866044.
10: Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res. 1991 Sep 15;51(18):4909-16. PubMed PMID: 1654205.
11: Vigevani A, Zampieri M, Pellizzato R. Thermal behaviour and binary phase diagram of (S)-(+)-4,4′-(1-methyl-1,2-ethandiyl)-bis-(2,6-piperazinedione) (dexrazoxane), a cardioprotective agent, and of its (R)-(-)-enantiomer. J Pharm Biomed Anal. 1992 Jan;10(1):31-6. PubMed PMID: 1391080.
12: Sargent JM, Williamson CJ, Yardley C, Taylor CG, Hellmann K. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562. Br J Cancer. 2001 Apr 6;84(7):959-64. PubMed PMID: 11286477; PubMed Central PMCID: PMC2363849.
13: Rhomberg W, Gruber-Mösenbacher U, Eiter H, Fritzsche H, Breitfellner G. [Prognosis and epidemiology of malignant hemangioendotheliomas of the thyroid gland]. Schweiz Med Wochenschr. 1993 Sep 4;123(35):1640-4. German. PubMed PMID: 8211014.
14: Thirupathi C, Nagesh Kumar K, Srinivasu G, Lakshmi Narayana C, Parameswara Murthy C. Development and Validation of Stereo Selective Method for the Separation of Razoxane Enantiomers in Hydrophilic Interaction Chromatography. J Chromatogr Sci. 2018 Feb 1;56(2):147-153. doi: 10.1093/chromsci/bmx094. PubMed PMID: 29140426.
15: Xue Y, Guo Y, Xie X. Translocation t(7;11)(P15;P15) in a patient with therapy-related acute myeloid leukemia following bimolane and ICRF-154 treatment for psoriasis. Leuk Res. 1997 Feb;21(2):107-9. PubMed PMID: 9112426.
16: Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM. A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol. 1995 Sep 28;50(7):953-8. PubMed PMID: 7575679.
17: Xue Y, Lu D, Guo Y, Lin B. Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res. 1992 Nov;16(11):1113-23. PubMed PMID: 1434747.
18: Potácová A, Adamcová M, Cajnáková H, Hrbatová L, Sterba M, Popelová O, Simůnek T, Ponka P, Gersl V. Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents. Physiol Res. 2007;56(2):251-4. PubMed PMID: 17504005.
19: Loyevsky M, Sacci JB Jr, Boehme P, Weglicki W, John C, Gordeuk VR. Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures. Exp Parasitol. 1999 Feb;91(2):105-14. PubMed PMID: 9990337.
20: Diop NK, Vitellaro LK, Arnold P, Shang M, Marusak RA. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem. 2000 Feb;78(3):209-16. PubMed PMID: 10805177.

Request a Quote